Cowen analyst Phil Nadeau weighed in on Atara Biotherapeutics (NASDAQ: ATRA) after the company provided an update on regulatory filing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE